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OBJECTIVES: To develop best practices, tools, capacity and capability for an effec-
tive formulary management system for five public health care institutions in
Singapore. METHODS: A survey was conducted among formulary committee
members of the participating institutions as part of gap analysis. A cross-institu-
tion task force comprising decision makers, clinicians, pharmacists and health
technology assessment (HTA) researchers from participating institutions was
formed to recommend best practices for formulary submission, evidence review
and synthesis, pharmacoeconomic evaluation and criteria for decision making.
Endorsement fromparticipating institutions’ stakeholderswas obtained before the
implementation of this programme. RESULTS: The gap analysis highlighted three
key areas for improvement: 1) methodologies for evidence review and synthesis,
and pharmacoeconomic evaluation; 2) criteria for formulary decision making; and
3) capacity and capability building especially in pharmacoeconomics. A set of tools
that facilitate evidence review and synthesis including guidelines for pharmaco-
economic evaluation was developed with reference to published literatures and
international guidelines. Clinical need, safety, efficacy, cost-effectiveness, budget
impact and opinion from subject matter experts were deemed as important deci-
sion-making criteria. A decision-making form incorporating these criteria was cre-
ated to facilitate the consistency and transparency of the decisionmaking process.
Workshops focused on HTA were conducted to equip pharmacists supporting for-
mulary management for participating institutions the knowledge and skills to ap-
praise clinical and economic evidence. In addition, a team comprising personnel
trained in pharmacoeconomics was set up to provide support to institutions phar-
macists on the application of HTA via joint review on selected new drug
applications. CONCLUSIONS: Support from participating institutions formulary
committees and seniormanagement are keys for the successful implementation of
this programme. Moving forward, the challenge is to integrate the proposed
changes into current practice.
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OBJECTIVES: To evaluate doctors’ knowledge, attitude and practices on Malaysian
CPG 2008 along with factors predicting guidelines adherence and hypertension
control. METHODS: This was a co-relational study conducted at Hospital Pulau
Pinang, Malaysia. A total of 26 doctors were enrolled. Doctors’ knowledge and
attitude onCPG (2008)were evaluated through a valid and reliable questionnaire. In
order to evaluate doctors’ actual prescribing practices, prescriptions written by 26
enrolled doctors to 650 established hypertensive outpatients (25 prescriptions per
doctor) were noted on visit one. The noted prescriptions were classified either as
compliant or noncompliant to CPG (2008). Five hundred and twenty enrolled pa-
tients (20 patients per doctor) were followed for one more visit. Blood pressure
noted on visit 2 was related to the prescription written on visit one. SPSS 16 was
used for data analysis. RESULTS: Nineteen doctors (73.07%) had adequate knowl-
edge of CPG (2008). Doctors were highly positive towards CPG (2008) with mean
attitude score of 23.151.34 points on a 30 point scale. Statistically significant
correlation (rs0.635, p-value0.001) was observed between doctors’ knowledge
and practice scores. The majority (67.1%) patients received guidelines compliant
therapy. In multivariate analysis hypertension clinic (OR0.398, p-value0.008)
was the strong predictor of poor adherence with guidelines. On visit Two 51%
patients were at goal BP. In multivariate analysis, Angiotensin converting enzyme
inhibitors (OR2.100, p-value0.001) and guidelines adherence (OR1.745,
p-value0.022) were the strong predictors of hypertension control, while renal dis-
ease (OR0.283, p-value0.001), diabetes mellitus (OR0.598, p-value0.025) and
diabetic clinic (OR0.384, p-value0.024) were the strong predictors of poor control
of hypertension. CONCLUSIONS: An overall fair level of doctors’ knowledge, ad-
herence with guidelines and control of hypertension was observed. The gaps be-
tween what guidelines recommended and clinical practice was especially seen in
the pharmacotherapy of uncomplicated hypertension and hypertension with dia-
betes mellitus and renal disease.
PHP105
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OBJECTIVES: To assess the current practice for the management of long term
asthma inMalaysia and the prescribing pattern among asthmatic patients by using
medication assessment tools (MAT). The MAT was developed according to guide-
line used by the physicians in Selayang Hospital.METHODS: The development and
validation of asthma MAT had undergone a process that involved selection of
guideline on long termasthmamanagement in adults. The recommendationswere
focused on pharmacologic management. Updated version of GINA guidelines was
used as GINA guidelines is known to be used in the management of long term
asthmatic patients in Selayang Hospital. The MAT tool was then discussed and
validated together with practising pharmacist. Pilot sampling was done and data
was then collected from patient medical record in Selayang Hospital. These data
were then assessed using Microsoft Access and Microsoft Excel. RESULTS: The
result showed that level of adherence towards guidelines used was 86.3% for 73
asthmatic patients that were selected. If magnification was made, however, the
reduction of current medication dose had not been made after the symptoms of
asthma have been controlled and only 39.4% had their dose reduced according to
the guideline. CONCLUSIONS: The adherence of guidelines seem to be high, how-
ever, improvement needs to bemade in reducing the dose once patients’ asthmatic
symptoms have been resolved.
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Clinical guidelines recommend patients with Diffuse Large B-Cell Lymphoma (DL-
BCL) receive anthracycline-based chemotherapy (ABC) treatment. During the
1990s, however, about one- third of elderly DLBCL patients did not receive chemo-
therapy, potentially due to intolerance of toxicities associated with ABC. With the
addition of rituxmab in the late 1990s, it appears that physicians choose to use
non-guideline rituximab plus non-ABC chemotherapy for patients with low toxic-
ity tolerance. OBJECTIVES: This study assesses the diffusion of the use of non-
guideline chemotherapy treatment for elderly DLBCL patients and examines the
regional variation in diffusion.METHODS:A retrospective cohort consisting of 5839
Medicare beneficiaries diagnosed in 2000-2006 with primary DLBCL at age 66 or
older treated with any chemotherapy was selected from the 2007 Surveillance,
Epidemiology and End Results (SEER)-Medicare linked database. Patients were ex-
cluded if physician information was not available (N55). Patient chemotherapy
was categorized usingMedicare claimswithin fivemonths of diagnosis. Physicians
(N3,072) were included if they prescribed any chemotherapy to patients during
the initial treatment period. Descriptive analyses were used to characterize varia-
tion in chemotherapy treatment across the SEER registry regions. RESULTS: Phy-
sicians prescribed ABC chemotherapy to on average 81.2% of received chemother-
apy patients. A totla of 19.8% of physicians, however, prescribed rituximab plus
non-ABC chemotherapy to at least one patient. The percentage of physicians
whom used rituximab plus non-ABC chemotherapy increased from 1.4% in 2000 to
16.1% in 2006. Louisiana, Connecticut, and Seattle were the top three SEER regions
where over 23% of the physicians prescribed this alternative chemotherapy. In
Hawaii, New Mexico, and Iowa SEER regions less that 14% of physician used this
alternative chemotherapy. CONCLUSIONS: The percentage of physicians having
adopted rituximab plus non-ABC chemotherapy as the alternative treatment in-
creased over the years. Physicians’ adoption of non-guideline treatment varies
across regions.
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OBJECTIVES: HCC has a substantial disease burden worldwide, especially in AP.
The global HCC BRIDGE study is the first global, large-scale, observational study to
document real-world treatment pattern and outcomes of HCC patients from diag-
nosis to death. METHODS: This longitudinal cohort study includes HCC patients
newly diagnosed between January 2005 and June 2011 and treated atmajormedical
centers, with data collected retrospectively and prospectively as recorded in pa-
tient charts. RESULTS: In the first interim analysis (July 2011), 8909 patients (mean
age, 54 years; 83% male) were enrolled in AP (China, n6295; Taiwan, n1183;
Korea, n1136; Japan, n295). The predominant risk factorwasHBV inChina (80%),
Taiwan (67%), and Korea (77%), and HCV in Japan (69%). The predominant BCLC
stage at diagnosiswas stage C in China (56%) andKorea (51%) and stageA in Taiwan
(55%) and Japan (47%). Variations were noted between China, Taiwan, Korea, and
Japan in first-recorded treatment with resection/transplant (31%, 51%, 23%, 14%),
TACE (53%, 27%, 55%, 24%), other locoregional therapy (9%, 18%, 8%, 52%), and
systemic therapy (2%, 3%, 11%, 13%). There also were variations in treatment ever
used with resection/transplant (34%, 53%, 29%, 16%), TACE (61%, 37%, 65%, 28%),
other locoregional therapy (17%, 30%, 17%, 64%), and systemic therapy (5%, 9%,
30%, 19%). Recorded treatment by line of therapy, BCLC and mUICC stage, and
country will be presented from the second interim analysis, which will include
17,000 patients. Actual practice and expected practice according to guidelineswill
be evaluated, including how access issues may affect treatment availability.
CONCLUSIONS: The global HCC BRIDGE study, which is the largest study of its kind
(in approximately 19,000 patients), provides valuable insights into global HCC dis-
ease characteristics and patient management. Although AP has the highest HCC
burden, practice approaches differ across the region.
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OBJECTIVES: During hajj season, more than 2 million hajj pilgrims would be occu-
pying the holy land Makkah with area of 164,000 km2. On the observation many of
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